Glofitamab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD20 and CD3 |
| Clinical data | |
| Trade names | Columvi |
| Other names | RO7082859, glofitamab-gxbm |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C8632H13326N2296O2701S58 |
| Molar mass | 194344.41 g·mol−1 |
Glofitamab, sold under the brand name Columvi, is a bispecific monoclonal antibody used for the treatment of large B-cell lymphoma. It is a bispecific CD20-directed CD3 T-cell engager developed by Roche.
The most common side effects include cytokine release syndrome, muscle and bone pain, rash, and tiredness.
It was approved for medical use in Canada in July 2023, in the United States in June 2023, and in the European Union in July 2023.